

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 May 2001 (10.05.2001)

PCT

(10) International Publication Number
WO 01/32688 A1

- (51) International Patent Classification⁷: C07K 1/00, C12Q 1/00
- (21) International Application Number: PCT/US00/29976
- (22) International Filing Date: 30 October 2000 (30.10.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/162,584 29 October 1999 (29.10.1999) US
60/213,093 21 June 2000 (21.06.2000) US
60/223,805 8 August 2000 (08.08.2000) US
- (71) Applicant (for all designated States except US): RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY [US/US]; Old Queens, Somerset Street, New Brunswick, NJ 08903 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): WARD, William, W. [US/US]; 149 E. Chestnut Avenue, Metuchen, NJ 08840-1409 (US).
- (74) Agents: REED, Janet, E. et al.; Saul Ewing LLP, Centre Square West, 38th Floor, 1500 Market Street, Philadelphia, PA 19102-2186 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

BEST AVAILABLE COPY

WO 01/32688 A1

(54) Title: *RENILLA RENIFORMIS* GREEN FLUORESCENT PROTEIN

(57) Abstract: Green fluorescent protein (GFP) polypeptides from *Renilla reniformis* and *Renilla kollikeri* are disclosed. The amino acid sequence of *R. reniformis* GFP and back-translated nucleotide sequences of nucleic acids encoding the *R. reniformis* GFP are also disclosed. These isolated polypeptides, along with the pertinent amino acid and nucleotide sequence information, are useful in a variety of applications for which GFPs from other sources (e.g., *Aequoria*) are currently employed. Techniques for using the *Renilla* GFPs are disclosed, along with advantages of *Renilla* GFP as compared with currently available GFPs.

RENILLA RENIFORMIS GREEN FLUORESCENT PROTEIN

Pursuant to 35 U.S.C. §202(c), it is acknowledged that the U.S.
5 Government has certain rights in the invention described herein, which was made in
part with funds from a National Science Foundation-Advanced Technological
Education grant (DUE# 9602356).

This application claims priority to U.S. Provisional Application Nos.
60/162,584, filed October 29, 1999, 60/213,093, filed June 21, 2000 and
10 60/223,805, filed August 8, 2000, the entireties of which are incorporated by
reference herein.

FIELD OF THE INVENTION

This invention relates to the field of biotechnology research products,
15 fluorescent proteins, fluorescence microscopy, high throughput screening,
diagnostics, and the monitoring by fluorimetric remote sensing of agricultural and
environmental acreage. In particular, this invention provides a isolated or synthetic
green fluorescent protein (GFP), having amino acid sequence and functional features
of the GFP from *Renilla reniformis* and *Renilla kollikeri* and natural or synthetic
20 genes that encode *Renilla* GFPs.

BACKGROUND OF THE INVENTION

Various scientific and scholarly articles are referred to in parentheses
throughout the specification. These articles are incorporated by reference herein to
25 describe the state of the art to which this invention pertains.

Many species of coelenterates (jellyfish, hydroids, sea pansies, and
sea pens) are bioluminescent. A rise in the intracellular concentration of calcium
causes the oxidation of a protein-bound luciferin molecule, resulting in formation of
excited-state oxyluciferin. The oxyluciferin may emit blue light by direct de-
30 excitation or may transfer the energy by a radiationless mechanism to the non-

catalytic accessory protein, the green fluorescent protein (GFP), which subsequently emits green light.

Thus, GFP acts to shift the color of bioluminescence from blue to green in luminous coelenterates and to increase the quantum yield of light emission (Ward and Cormier, 1979, J. Biol. Chem. 254:781-788). Nearly all naturally occurring GFPs emit light with wavelength maxima in the 490-520 nm range, with most centered at 508-509 nm. The range of excitation maxima is however much broader, 395-498 nm (Ward, 1998, In Green Fluorescent Protein: Properties, Applications and Protocols, pp 45-75, ed. M. Chalfie and S. Kain, Wiley-Liss).

The jellyfish, *Aequorea victoria*, produces bioluminescence that is typical of the hydrozoan family of coelenterates. The *A. victoria* GFP is the best characterized of the GFPs. The gene for GFP was first isolated from *Aequorea* (Prasher et al., 1992, Gene 111:229-233) and later demonstrated capable of functional expression as a transgene (Chalfie et al., 1994, Science 263:802-805).

The isolation of the *Aequorea* GFP gene has led to a proliferation of GFP mutants and ever-increasing numbers of GFP applications. Key to the usefulness of this gene is that it needs no added substrates or cofactors (other than those factors found in typical *in vitro* translation reagents) to produce a functional gene product. It can be readily expressed in heterologous organisms. GFP as produced, fluoresces: it can shift the color of experimentally introduced blue or ultra-violet light to an emitted green light. It is therefore useful as a non-invasive marker in living cells, enabling applications such as cell lineage tracing, reporter gene expression, and measurement of protein-protein interactions.

Fluorescent GFP has been expressed as a functional transgene in a wide range of cells and/or organisms, including bacteria, yeast, slime mold, plants, *Drosophila*, zebra fish and mammalian cells. GFP can function as a useful protein tag because it tolerates C-terminal and N-terminal fusion to a broad range of proteins without loss of its fluorescent properties. Wild-type GFP is typically distributed in the cytoplasm and nucleus of heterologous cells in which it is expressed, but it can also be targeted to the nucleus, mitochondria, chloroplasts,

secretory pathways, plasma membrane or cytoskeleton by GFP gene fusions with sequences encoding specific targeting or with coding sequences of entire proteins.

Aequorea GFP is composed of 238 amino acids which provide a polypeptide size of approximately 27 kDa. It is the only known GFP molecule that
5 has an excitation maximum in the ultraviolet region, with its major excitation peak at 395 nm and a minor excitation peak at 475 nm. Its emission peak is at 508 nm. Conventional protein sequencing and gene sequencing of a wide variety of *Aequorea* GFP mutants as well as X-ray crystallography have lead to the identification of the chromophore, derived from residues 64-69 of the primary amino acid sequence
10 (Yang et al., 1996, Nature Biotechnology 14:1246-1251; Ward 1998, supra). Post-translational modifications of the protein result in a cyclized tripeptide originating from these residues. No other enzymes or cofactors are required for the cyclization of the apoprotein, however molecular oxygen is clearly required. Natural and induced mutations in the amino acid sequence of *Aequorea* GFP lead to shifts in the
15 absorbance spectrum, enhancements in fluorescence, and increases in temperature tolerance (Yang et al., 1996, supra).

Several variants and mutants of the *Aequorea* GFP have been discovered and developed. Some of these variants (especially those with variations in and around the chromophore) are known to have physical properties that are
20 advantageous in specific situations. These variations in *Aequorea* GFP are well known in the art (Yang et al., 1996, supra).

The GFP from the anthozoan coelenterates *Renilla reniformis* and *Renilla kollikeri*, the sea pansies, has many functional advantages over the *Aequorea* GFP. While its emission spectrum is very similar to *Aequorea* GFP (wavelength
25 max = 509 nm), the excitation (or absorption) spectrum of *Renilla* GFP is very different. *Renilla* GFP has excitation peaks at 498 nm and 470 nm, with a half band width of approximately 15 nm at both. In contrast, *Aequorea* GFP has excitation peaks at 393 nm and 473 nm, with a half band width of approximately 30 nm at both (Ward et al., 1980, Photochem. Photobiol. 31:611-615). The *Renilla*
30 GFP absorbs very little between 320 - 390 nm, where *Aequorea* GFP has considerable absorption. This region of low absorption is a strong asset to many

applications related to fluorescence microscopy where the 320 - 390 nm range could be used to excite a second "reporter" chromophore, such as DAPI, while the higher wavelength is used to excite the *Renilla* GFP. The transparent window (320 nm - 390 nm) in *Renilla reniformis* and *Renilla kollikeri* GFP excitation also facilitates mathematical noise subtraction in high throughput screening and in remote sensing applications where multiwavelength excitation is employed.

Renilla GFP also has a much higher extinction coefficient, 133,000 L * mol⁻¹ * cm⁻¹ at 498 nm as compared to 27,600 L * mol⁻¹ * cm⁻¹ at 397 nm for *Aequorea* GFP, while they both have similar quantum yields of 0.80. This higher extinction coefficient is a great benefit to all uses of GFP, but particularly so in application for *in vivo* expression in such diverse fields as high throughput screening, diagnostics, and the remote fluorimetric monitoring of agricultural and environmental change. The *Aequorea* GFP has proved adequate when expressed by a strong promoter, but often inadequate when fused to a weaker promoter. Many applications that seek to characterize the *in vivo* regulation of a weaker promoter need a "brighter" GFP in order to succeed. Moreover, the higher stability of *Renilla* GFP when subjected to pH extremes, detergents and chaotropic agents has general advantages in many *in vitro* applications such as fixation of tissue and diagnostic kits.

While a great deal is known about the physical properties of *Renilla* GFP, little is known about its amino acid sequence or the nucleic acid sequence of its gene, presumably due to one or more factors including: (1) difficulty in obtaining the organism, (2) difficulty and complexity of purifying GFP from *Renilla*, and (3) difficulty in obtaining suitable DNA or RNA for cloning purposes. The GFP purified directly from *Renilla* is currently too costly to sell commercially and, in any event, tends to consist of a heterogeneous population, possibly the result of multiple GFP genes in the natural population or limited C-terminal truncation of the gene product as occurs in native *Aequorea* GFP.

Having the complete sequence of the *Renilla reniformis* or *R. kollikeri* GFP would put this tool within the reach of the biotechnology community for cloning, expression and diagnostic and other applications. The six amino acid

residues corresponding to the chromophore region of *Renilla* GFP have been identified (San Pietro et al., 1993, Photochem. Photobiol. 57:63s), but this information is hardly enough to synthesize a protein with all the unique properties of *Renilla* GFP or to isolate native nucleic acids that encode it. Making the *Renilla* GFP protein and nucleic acids available would enable a new range of GFP applications.

SUMMARY OF THE INVENTION

In accordance with the present invention, the amino acid sequence of *Renilla reniformis* GFP has now been determined. From this information, it is now possible to produce a synthetic GFP having the defining characteristics of *R. reniformis* GFP. It is also possible to design and produce nucleic acid molecules encoding the *Renilla reniformis* GFP.

According to one aspect of the invention, a synthetic green fluorescent protein (GFP) is provided. This protein has the sequence of the *Renilla* GFP set forth in SEQ ID NO:1. The synthetic GFP of the invention has excitation peaks at 470 nm and 498 nm, and an emission peak at 509 nm, and a transparent absorbance window from 320-390 nm. The synthetic *Renilla* GFP also has a very high molar extinction coefficient, 133,000 at 498 nm, making it ideal for applications where the current standard *Aequorea* GFP is not intense enough. Additionally, the *Renilla* GFP is stable at high and low pH extremes, in 8 M urea, 6 M guanidine hydrochloride and 1% SDS. Because of its transparent absorbance window from 320 nm to 390 nm, the synthetic *Renilla* GFP is better suited than *Aequorea* GFP for techniques involving double fluorescent-labeling. In addition, the transparent absorption window that exists in *Renilla* GFP provides a mechanism of noise suppression (removal of autofluorescence and scatter) with the use of polychromatic excitation. The broader stability range also allows the synthetic *Renilla* GFP to be used in applications where *Aequorea* GFP would lose fluorescence signal.

According to a second aspect of the invention, a nucleic acid molecule that encodes *Renilla* GFP is provided. In a preferred embodiment, the

nucleic acid encodes the protein sequence defined in SEQ ID NO:1. In another preferred embodiment, the nucleic acid encodes the amino acid sequence of SEQ ID NO:1 and is isolated from *Renilla*. In another preferred embodiment, the nucleic acid encodes the amino acid sequence of SEQ ID NO:1 using optimized mammalian or prokaryotic codon usage.

Also provided in accordance with the present invention are standard GFPs. Such standards are useful in order to allow calibration of many fluorescence-based biological assays as well the fluorescence measuring instruments. These standards are also provided as kits for ease of use, wherein standard concentrations or dilutions are provided, along with certification of the standard properties and biophysical parameters, and instructions for use. A method for the use of such standards in calibrating instruments and fluorescence-based assays is further provided.

Further provided in the present invention are antibodies to the GFPs of the invention. These antibodies are useful for a variety of purposes; they are particularly of use in purification and characterization of the GFPs and variants thereof. In addition to the antibodies to the GFP, the instant invention includes antibodies which are fused to or tagged by a GFP molecule. These antibodies, which still retain their useful binding characteristics are readily detected as they also provide the fluorescent properties of the GFP. Such antibodies further include genetically-designed antibody fragments which can be expressed and purified. Typically these are produced from a gene construct which includes a sequence encoding a heavy chain, or binding fragment of an immunoglobulin molecule fused in-frame with a GFP-encoding sequence. Such immuno-GFP molecules are useful for a variety of purposes including hybrid assays with the specificity of immunoassays and the improved detection of GFP fluorescent assays. The use of GFPs in this capacity also provides for use of multiple fluorescent tags within the immunoassays.

A method for the reduction of background noise in fluorescence-based biological assays is also provided. This method is facilitated by the window of low absorbance in the GFP of the present invention. Other GFPs lack a window

of low absorbance from 320 nm through 390 nm, whereas the Renilla GFPs of the instant invention have near-transparent window of absorption in this range. This can be utilized to reduce background significantly and to greatly increase the signal-to-noise ratio, allowing more sensitive detection in biological assays based on

5. fluorescence detection.

Other features and advantages of the present invention will be better understood by reference to the figure and detailed description that follow.

BRIEF DESCRIPTION OF THE DRAWINGS

10 **Fig. 1.** Absorption spectrum of *Renilla kollikeri* GFP.

DETAILED DESCRIPTION OF THE INVENTION

I. Definitions

Various terms relating to the biological molecules of the present invention are used throughout the specifications and claims. Where used herein, "isolated" means altered "by the hand of man" from the natural state. If a composition or substance occurs in nature, it has been "isolated" for example, when changed or removed from its original environment. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state, or present through synthetic means, is "isolated", as the term is employed herein.

With reference to nucleic acids of the invention, the term "isolated nucleic acid" is sometimes used. This term, when applied to genomic DNA, refers to a DNA molecule that is separated from sequences with which it is immediately contiguous (in the 5' and 3' directions) in the naturally-occurring genome of the organism from which it was derived. For example, the "isolated nucleic acid" may comprise a DNA molecule inserted into a vector, such as a plasmid or virus vector, or integrated into the genomic DNA of a procaryote or eukaryote. An "isolated nucleic acid molecule" may also comprise a cDNA molecule or a synthesized

nucleic acid molecule. An "isolated nucleic acid" also may be a synthetic nucleic acid.

With respect to RNA molecules of the invention the term "isolated nucleic acid" primarily refers to an RNA molecule encoded by an isolated DNA molecule as defined above. Alternatively, the term may refer to an RNA molecule that has been sufficiently separated from RNA molecules with which it would be associated in its natural state (i.e., in cells or tissues), such that it exists in a "substantially pure" form (the term "substantially pure" is defined below). Alternatively, an entire class of RNA molecules is sometimes deemed "isolated" when is separated from other biomolecules and/or other classes of RNA (e.g. tRNA and rRNA). For example, the class of polyadenylated RNA is often isolated in order to clone cDNA from a specific messenger RNA.

With respect to protein, the term "isolated protein" or "isolated and purified protein" is sometimes used herein. This term often refers to a protein which has been sufficiently separated from other proteins with which it would naturally be associated, so as to exist in "substantially pure" form. Alternatively, this term may refer to a protein produced by expression of an isolated nucleic acid molecule of the invention. An "isolated protein" also may be a synthetic polypeptide comprising naturally occurring or non-naturally occurring amino acid residues.

The term "polynucleotide" generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases

include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications have been made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as synthesized or as typically found in nature, as well as the
5 chemical forms of DNA and RNA characteristic of viruses and cells.
"Polynucleotide" also encompasses relatively short polynucleotides, often referred to as oligonucleotides. Such oligonucleotides could be isolated from nature or more typically, chemically synthesized.

The term "polypeptide" refers to any peptide or protein comprising
10 two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 amino acids represented by codons in the genetic code. "Polypeptides" include
15 amino acid sequences modified either by natural processes, such as post-translational modification or processing, or by chemical modification techniques which are well known in the art. Such modifications are described in basic texts and in more detailed monographs, as well as in extensive research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone,
20 the amino acid side-chains and the amino and/or carboxyl termini. It will be appreciated that the same type of modification may be present to the same extent or to varied extents at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Disulfide
25 bridges may form within or between polypeptide chains. Cyclic, branched and branched cyclic polypeptides may result from natural post-translational processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative,
30 covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation,

demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. See, for instance, **PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES**, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993 and Wold, F., **Posttranslational Protein Modifications: Perspectives and Prospects**, pgs. 1-12 in **POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS**, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth Enzymol* (1990) 182:626-646 and Rattan *et al.*, "Protein Synthesis: Posttranslational Modifications and Aging", *Ann NY Acad Sci* (1992) 663:48-62. In addition to these modifications and alterations of polypeptides, proteins may also associate with each other in various ways. Where used herein, "dimers" are an association of two proteins to form a single functional unit. "Homodimers" contain two identical subunits, while "heterodimers" contain two nonidentical subunits. "Multimers" contain two or more subunits per functional unit and may comprise identical and nonidentical polypeptide chains.

The term "substantially pure" refers to a preparation comprising at least 50-60% by weight the compound of interest (e.g., nucleic acid, oligonucleotide, protein, etc.). More preferably, the preparation comprises at least 75% by weight, and most preferably 90-99% by weight, the compound of interest. Purity is measured by methods appropriate for the compound of interest (e.g. chromatographic methods, agarose or polyacrylamide gel electrophoresis, HPLC analysis, and the like). Where used herein above the term "by weight" means the weight of the sample, exclusive of water and salts.

The term "substantially the same" refers to nucleic acid or amino acid sequences having sequence variation that do not materially affect the nature of the protein (i.e. the structure, stability characteristics, substrate specificity and/or biological activity of the protein). With particular reference to nucleic acid

sequences, the term "substantially the same" is intended to refer to the coding region and to conserved sequences governing expression, and refers primarily to degenerate codons encoding the same amino acid, or alternate codons encoding conservative substitute amino acids in the encoded polypeptide. With reference to amino acid sequences, the term "substantially the same" refers generally to conservative substitutions and/or variations in regions of the polypeptide not involved in determination of structure or function.

The terms "percent identical" and "percent similar" are also used herein in comparisons among amino acid and nucleic acid sequences. When referring to amino acid sequences, "identity" or "percent identical" refers to the percent of the amino acids of the subject amino acid sequence that have been matched to identical amino acids in the compared amino acid sequence by a sequence analysis program. "Percent similar" refers to the percent of the amino acids of the subject amino acid sequence that have been matched to identical or conserved amino acids. Conserved amino acids are those which differ in structure but are similar in physical properties such that the exchange of one for another would not appreciably change the tertiary structure of the resulting protein. Conservative substitutions are defined in Taylor (1986, J. Theor. Biol. 119:205). When referring to nucleic acid molecules, "percent identical" refers to the percent of the nucleotides of the subject nucleic acid sequence that have been matched to identical nucleotides in the comparison sequence.

"Identity" and "similarity" can be readily calculated by known methods. Nucleic acid sequences and amino acid sequences can be compared using computer programs that align the similar sequences of the nucleic or amino acids thus define the differences. The Blastn and Blastp 2.0 programs provided by the National Center for Biotechnology Information (at <http://www.ncbi.nlm.nih.gov/blast/>; Altschul et al., 1990, J Mol Biol 215:403-410) using a gapped alignment with default parameters, may be used to determine the level of identity and similarity between nucleic acid sequences and amino acid sequences.

With respect to single-stranded nucleic acid molecules, the term "specifically hybridizing" refers to the association between two single-stranded nucleic acid molecules of sufficiently complementary sequence to permit such hybridization under pre-determined conditions generally used in the art (sometimes
5 termed "substantially complementary"). In particular, the term refers to hybridization of an oligonucleotide with a substantially complementary sequence contained within a single-stranded DNA or RNA molecule, to the substantial exclusion of hybridization of the oligonucleotide with single-stranded nucleic acids of non-complementary sequence.

10 With respect to oligonucleotides, but not limited thereto, the term "specifically hybridizing" refers to the association between two single-stranded nucleotide molecules of sufficiently complementary sequence to permit such hybridization under pre-determined conditions generally used in the art (sometimes termed "substantially complementary") In particular, the term refers to
15 hybridization of an oligonucleotide with a substantially complementary sequence contained within a single-stranded DNA or RNA molecule of the invention, to the substantial exclusion of hybridization of the oligonucleotide with single-stranded nucleic acids of non-complementary sequence.

A "coding sequence" or "coding region" refers to a nucleic acid
20 molecule having sequence information necessary to produce a gene product, when the sequence is expressed. A "coding sequence" may be determined indirectly from a known polypeptide sequence by understanding the genetic code. Since each amino acid is coded for by a codon containing three nucleotide bases, it is easy to 'back-
translate from a polypeptide sequence to a corresponding nucleotide sequence using
25 a simple table of codon and their amino acid equivalents. Redundancy in the genetic code and "wobble" allow many possible "degenerate" sequences to encode the polypeptide of interest. A specific choice of a representative nucleotide sequence may be made on the basis of codon usage preference or codon bias, or degenerate sequences can be used for purposes where the ambiguity can be tolerated. Many of
30 the commonly available molecular biology and/or molecular genetic computer

packages provide a back-translation function. Other back-translation applications are available for public use or free download on the Internet.

Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for the expression of a coding sequence in a host cell.

The terms "promoter", "promoter region" or "promoter sequence" refer generally to transcriptional regulatory regions of a gene, which may be found at the 5' or 3' side of the coding region, or within the coding region, or within introns. Typically, a promoter is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. The typical 5' promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence is a transcription initiation site (conveniently defined by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.

The term "operably linked" or "operably inserted" means that the regulatory sequences necessary for expression of the coding sequence are placed in a nucleic acid molecule in the appropriate positions relative to the coding sequence so as to enable expression of the coding sequence. This same definition is sometimes applied to the arrangement other transcription control elements (e.g. enhancers) in an expression vector.

A "vector" is a replicon, such as plasmid, phage, cosmid or virus, to which another nucleic acid segment may be operably inserted so as to bring about the replication or expression of the segment.

The term "nucleic acid construct" or "DNA construct" refers to genetic sequence used to transform cells or organisms. The term is sometimes used to refer to a coding sequence or sequences operably-linked to appropriate regulatory sequences and inserted into a vector. This term may be used interchangeably with

the term "transforming DNA". Such a nucleic acid construct may contain a coding sequence for a gene product of interest, along with a selectable marker gene and/or a reporter gene. The transforming DNA may be prepared according to standard protocols such as those set forth in "Current Protocols in Molecular Biology", eds.

- 5 Frederick M. Ausubel et al., John Wiley & Sons, 1999. Methods of transformation are specific to the kinds of cells transformed and are well known in the art.

The term "selectable marker gene" refers to a gene encoding a product that, when expressed, confers a selectable phenotype such as antibiotic
10 resistance on a transformed cell.

The term "reporter gene" refers to a gene that encodes a product which is readily detectable by standard methods, either directly or indirectly.

A "heterologous" region of a nucleic acid construct is an identifiable segment (or segments) of the nucleic acid molecule within a larger molecule that is
15 not found in association with the larger molecule in nature. Thus, when the heterologous region encodes a mammalian gene, the gene will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism. In another example, a heterologous region is a construct where the coding sequence itself is not found in nature (e.g., a cDNA where the genomic coding
20 sequence contains introns, or synthetic sequences having codons different than the native gene). Allelic variations or naturally-occurring mutational events do not give rise to a heterologous region of DNA as defined herein. The term "DNA construct", as defined above, is also used to refer to a heterologous region, particularly one constructed for use in transformation of a cell.

25 A cell has been "transformed" or "transfected" by exogenous or heterologous DNA when such DNA has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming DNA may be maintained on an episomal element such as a plasmid.
30 With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that it is inherited

by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. A "clone" is a population of cells derived from a single cell or common ancestor by mitosis. A
5 "cell line" is a clone of a primary cell that is capable of stable growth *in vitro* for many generations.

"Variant", as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties. A typical variant of a polynucleotide differs in
10 nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical
15 variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A
20 substituted or inserted amino acid residue may or may not be one represented in the genetic code. A variant of a polynucleotide or polypeptide may be naturally occurring such as an allelic variant, or a single nucleotide polymorphism (SNP) or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis
25 techniques or by direct synthesis.

The term "antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as F_{ab} fragments, including the products of an F_{ab} or other immunoglobulin expression library. With respect to the antibodies of the invention, the term, "immunologically
30 specific" refers to antibodies that bind to one or more epitopes of a protein of

interest, but which do not substantially recognize and bind other molecules in a sample containing a mixed population of antigenic biological molecules.

II. Description

5 Provided in accordance with the present invention is a green fluorescent protein (GFP), isolated from *Renilla reniformis* or synthesized to comprise a functionally equivalent amino acid sequence as that of the native *Renilla reniformis* GFP. *Renilla* GFP has several highly advantageous properties as compared with *Aequorea victoria* GFP, including an improved absorption spectrum,
10 a higher molar extinction coefficient and improved stability.

 GFP was purified from *Renilla reniformis* using previously described methods (Ward and Cormier, 1979, supra) . The GFP protein preparations were considered pure enough for protein sequencing when the ratio of absorbance at 498 nm to 280 nm was over 5.5. The purified polypeptide was fragmented by chemical
15 and/or enzymatic means and the resulting overlapping fragments were subjected to HPLC, mass spectroscopy, and amino acid sequence analysis. Sequences of the fragments were aligned based on sequence overlaps to generate the polypeptide sequence set forth in SEQ ID NO:1.

 Referring to SEQ ID No 1, in preferred embodiments, residues 124-
20 127 are composed of the amino acid sequence Tyr-X₁-Gly-X₂, where X₁ is Lys or Arg and X₂ is Ser or Asn. In a more preferred embodiment, when X₁ is Arg, X₂ is Asn or when X₁ is Lys, X₂ is Ser. In another preferred embodiment, residue 128 is a Lys, if residue is not a Lys than it is absent in other embodiments. In other preferred embodiments, residue 129 is Asp, Gly or Asn; residue 130 is Leu or Pro;
25 residue 131 is Arg or Pro; and residue 132 is Glu, Arg, Leu, Ser or Asp. In another preferred embodiment, the residue at position 162 is a Cys, Trp or Thr, while in other preferred embodiments the residue is modified or a degradation product of Cys, Trp, or Thr. In another preferred embodiment, residues 217 and 218 are Thr or Glu and Thr or Gly respectively. In another preferred embodiment,
30 the C-terminal portion of the protein extends beyond the proline residue 234, comprising the three amino acid sequence Glu-Trp-Val. In other embodiments the

C-terminus contains other extensions or modifications, while in some embodiments such modifications are absent. In another embodiment, the N-terminal region of the protein is blocked or modified by one or more unusual or modified amino acids.

The *Renilla* GFP amino acid sequence of SEQ ID NO:1 contains at
5 residues 65-67, the chromophore characterized in *Aequorea* GFP. The *Renilla* sequence of this invention also contains an Arg residue at position 95 and a Glu at position 218. These two amino acids are present in all GFPs sequenced to date (numbered as residues 96 and 222, respectively, in *Aequoria* GFP) and have been postulated by Ward to be critical in productively interacting with the chromophore
10 (Ward, 1998, In Green Fluorescent Protein: Properties, Applications and Protocols, pp 45-75, ed. M. Chalfie and S. Kain, Wiley-Liss). Because of the similarities in biological functions, physical properties, amino acid sequence and composition, the tertiary structure of *Renilla* GFP had been expected to be very similar to *Aequorea* GFP (Yang et al., 1996 supra).

15 Due to the general unavailability of *Renilla reniformis* and the difficulty associated with purifying significant quantities of GFP from the organism itself, preferred methods of making the GFP of the present invention include: (1) synthesizing the polypeptide, using the amino acid sequence information set forth herein; and (2) back-translating the amino acid sequence to generate a nucleotide
20 sequence, then synthesizing the nucleic acid and expressing it in an appropriate expression vector. In connection with this second method of making the GFP, and as discussed in greater detail below, a particularly preferred embodiment of back-translation employs codon preferences of the organism in which the GFP is desired to be expressed.

25 A GFP produced by the aforementioned methods and having the amino acid sequence of SEQ ID NO:1 is expected to possess the features of native *Renilla* GFP. *Renilla* GFP has excitation peaks at 470 nm and 498 nm, an emission peak at 509 nm and a region of low absorbance from 320-390 nm. The *Renilla* GFP also has a very high extinction coefficient, 133,000 at 498 nm. Additionally, this
30 GFP is stable in 8 M urea, 6 M guanidine hydrochloride, 1 % SDS and at high and low pH extremes

GFPs with amino acid residue variations, similar to those characterized in *Aequorea*, are very likely to have counterparts in *Renilla*; such mutations and variations will produce similar useful phenotypic changes in *Renilla* GFP. Mutants, including single nucleotide polymorphisms (SNPs) with these types
5 of variations in amino acid sequence, are considered part of the present invention. Some of these types of variations are described in Ward (1998, supra), and in commonly-owned, co-pending U.S. Application No. 60/104,563, all of which are incorporated by reference herein.

10 **III. Preparation of *Renilla reniformis* GFP Proteins,
Antibodies and Nucleic Acid Molecules**

A. Synthesis of *Renilla* GFP Protein

The synthetic *Renilla* GFP protein of the present invention may be
15 prepared by various synthetic methods of peptide synthesis via condensation of one or more amino acid residues, utilizing conventional peptide synthesis methods. Preferably, peptides are synthesized according to standard solid-phase methodologies, such as may be performed on an Applied Biosystems Model 430A peptide synthesizer (Applied Biosystems, Foster City, CA), according to
20 manufacturer's instructions. Other methods of synthesizing peptides or peptidomimetics, either by solid phase methodologies or in liquid phase, are well known to those skilled in the art.

When solid-phase synthesis is utilized, the C- terminal amino acid is linked to an insoluble carrier that can produce a detachable bond by reacting with a
25 carboxyl group in a C-terminal amino acid. One preferred insoluble carrier is p-hydroxymethylphenoxymethyl polystyrene (HMP) resin. Other useful resins include, but are not limited to, phenylacetamidomethyl (PAM) resins for synthesis of some N-methyl-containing peptides (this resin is used with the Boc method of solid phase synthesis) and MBHA (p-methylbenzhydrylamine) resins for producing
30 peptides having C-terminal amide groups.

During the course of peptide synthesis, amino acid functional groups may be protected/deprotected as needed, using commonly-known protecting groups. For instance, side-chain functional groups consistent with Fmoc synthesis are protected as follows: arginine (2,2,5,7,8-pentamethylchroman-6-sulfonyl),
5 asparagine (O-t-butyl ester), cysteine, glutamine and histidine (trityl), lysine (t-butyloxycarbonyl), serine and tyrosine (t-butyl). Modification utilizing alternative protecting groups for peptides and peptide derivatives will be apparent to those of skill in the art.

10 **B. Production of *Renilla* GFP by Expression of a GFP-Encoding Nucleic Acid Molecule**

The availability of amino acid sequence information, such as the sequence in SEQ ID NO:1, enables the preparation of a synthetic gene that can be
15 used to synthesize the *Renilla* GFP protein via standard *in vitro* and *in vivo* expression systems. The sequence encoding *Renilla* GFP from isolated native nucleic acid molecules can be utilized as well. Alternately, an isolated nucleic acid that encodes the amino acid sequence of the invention can be prepared by oligonucleotide synthesis. In a preferred embodiment, codon usage tables are used
20 to design a synthetic sequence that is particularly suited for a preferred organism. In a preferred embodiment, the codon usage table is derived from the organism in which the synthetic nucleic acid is expressed. For example, the codon usage for *E. coli* is used to design a DNA construct for expression of the *Renilla* GFP in *E. coli*. Organisms of interest include, but are not limited to, *Renilla reniformis*, *Renilla*
25 *kollikeri*, other *Renilla* species, *E. coli*, yeast, insects plants, and mammals. In a preferred embodiment, preference is given to mammalian codon usage, for expression in mouse cells. In other preferred embodiments, codon usage for humans is used. GFP so expressed may find preferential use for example in certain diagnostic applications or in the field of experimental medicine. In a more preferred
30 embodiment, a humanized GFP is designed with C-terminal His tags to facilitate purification after expression in a suitable cell expression system.

Synthetic oligonucleotides may be prepared by the phosphoramidite method employed in the Applied Biosystems 38A DNA Synthesizer or similar devices. The resultant oligonucleotide(s) may be purified according to methods known in the art, such as high performance liquid chromatography (HPLC). Long, double-stranded polynucleotides must be synthesized in stages, due to the size limitations inherent in current oligonucleotide synthetic methods. Thus, for example, a 1 kb double-stranded molecule may be synthesized as several smaller segments of appropriate complementarity. Complementary segments thus produced may be annealed such that each segment possesses appropriate cohesive termini for attachment of an adjacent segment. Adjacent segments may be ligated by annealing cohesive termini in the presence of DNA ligase to construct an entire 1.0 kb double-stranded molecule. A synthetic DNA molecule so constructed may then be cloned and amplified in an appropriate vector.

The availability of nucleic acids molecules encoding the *Renilla* GFP enables production of the protein using expression methods known in the art. According to a preferred embodiment, the protein may be produced by expression in a suitable expression system. For example, part or all of a DNA molecule, such as a DNA encoding the amino acid sequence of SEQ ID NO:1, may be inserted into a plasmid vector adapted for expression in a bacterial cell, such as *E. coli*, or a eukaryotic cell, such as *Saccharomyces cerevisiae* or other yeast. Such vectors comprise the regulatory elements necessary for expression of the DNA in the host cell, positioned in such a manner as to permit expression of the DNA in the host cell. Such regulatory elements required for expression include promoter sequences, transcription initiation sequences and, optionally, enhancer sequences. Appropriate expression systems include, but are not limited to: *E. coli*, the baculovirus system, *Picia* spp., yeast and *Arabidopsis* spp.

Alternatively, a cDNA or gene may be cloned into an appropriate *in vitro* transcription vector, such as pSP64 or pSP65 for *in vitro* transcription, followed by cell-free translation in a suitable cell-free translation system, such as wheat germ or rabbit reticulocytes. *In vitro* transcription and translation systems are

commercially available, e.g., from Promega Biotech (Madison, WI) or BRL (Rockville, MD).

The GFP produced by gene expression *in vitro* or in a recombinant procaryotic or eukaryotic system may be purified according to methods known in the art. In a preferred embodiment, a commercially available expression/secretion system can be used, whereby the recombinant protein is expressed and thereafter secreted from the host cell, to be easily purified from the surrounding medium. If expression/secretion vectors are not used, an alternative approach involves purifying the recombinant protein by affinity separation, such as by immunological interaction with antibodies that bind specifically to the recombinant protein or fusion proteins such as His tags. Such methods are commonly used by skilled practitioners. In addition, the unusual chemical stability of the *Renilla* GFP can be used to facilitate its purification. A mixture of expression products can be raised or lowered to a pH that denatures most other proteins, but leaves the stable GFP intact. The intact protein is then separated from the degraded or denatured proteins. Likewise, chaotropic agents such as 8 M urea or 6 M guanidine hydrochloride, or detergents such as 1 % SDS (sodium lauryl sulfate) can be used to selectively denature proteins while leaving *Renilla* GFP intact.

The *Renilla* GFP of the invention, prepared by one of the aforementioned methods, may be analyzed according to standard procedures. For example, the protein may be subjected to amino acid composition or amino acid sequence analysis, according to known methods. The stability and biological activity of the synthetic protein may be determined according to standard methods by characterizing the spectral properties of the protein and comparing them to those of native *Renilla* GFP (see Ward et al., 1979, *supra*). The purity of the protein may be assessed by determining the ratio of 498 nm to 280 nm absorbance, with a pure preparation having a ratio of approximately 6.0. The protein may be quantified by standard methods well known in the art.

In addition, batches of *Renilla* GFP after analysis and determination of purity as in the above, can be used to make standardized GFP. Lack of proper standards forces most GFP assays to be strictly qualitative. The use of standardized

GFP will allow great advances in using GFP in quantitative assays. Standardized GFP will allow simple calibration of instruments and calibration of assays, ensuring that quantitation and detection are optimized. Standardized GFP are enabled by the novel spectral properties of the proteins of this invention, and when used in combination with the assays of this invention, and/or in combination with the reduction in background or the increase of fluorescence signal to noise ratio enabled by the proteins and methods of this invention will further enable substantial improvements in quantitation accuracy and lowered detection limits. Such standards can also be made available as kits or as parts of kits for assays or for calibration of instruments used in fluorescence measurement.

C. Antibodies Immunologically Specific to *Renilla* GFP

The present invention also provides antibodies that are immunologically specific to the *Renilla reniformis* or *R. kollikeri* GFPs, or selected epitopes of the GFPs of the invention. Polyclonal antibodies may be prepared according to standard methods. In a preferred embodiment, monoclonal antibodies are prepared, which are immunologically specific to various epitopes of the protein. Monoclonal antibodies may be prepared according to general methods of Köhler and Milstein, following standard protocols. Polyclonal or monoclonal antibodies which are immunologically specific to the *Renilla* GFP can be utilized for identifying and purifying such proteins. For example, antibodies may be utilized for affinity separation of proteins with which they are immunologically specific or to quantify the protein. Antibodies may also be used to immunoprecipitate proteins from a sample containing a mixture of proteins and other biological molecules.

D. Isolation of Native *Renilla* GFP Nucleic Acid Molecules

Nucleic acid molecules encoding the *Renilla* GFP may be isolated from appropriate *Renilla* strains using methods well known in the art. However, the isolation of nucleic acids from *Renilla* is not trivial, inasmuch as *R. reniformis* appears to comprise many nucleases and other components that interfere with the isolation of intact DNA and RNA.

However, once an appropriate sample of mRNA or genomic DNA is obtained, a cDNA or genomic DNA library can be constructed using standard

methods. Native nucleic acid sequences may be isolated by screening *Renilla* cDNA or genomic libraries with oligonucleotides designed to match the *Renilla* coding sequence of GFP. In positions of degeneracy, where more than one nucleic acid residue could be used to encode the appropriate amino acid residue, all the appropriate nucleic acids residues may be incorporated to create a mixed oligonucleotide population, or a neutral base such as inosine may be used. The strategy of oligonucleotide design is well known in the art (see also Sambrook et al., Molecular Cloning, 1989, Cold Spring Harbor Press, Cold Spring Harbor NY).

Alternatively, PCR (polymerase chain reaction) primers may be designed by the above method to match the *Renilla* coding sequence of GFP, and these primers used to amplify the native nucleic acids from isolated *Renilla* cDNA or genomic DNA. In a preferred embodiment, a cDNA clone is isolated from *Renilla reniformis*. In another preferred embodiment, a genomic clone is isolated from *Renilla reniformis*. In a highly preferred embodiment, the cDNA or the genomic clone isolated contain sequences which encode a polypeptide substantially the same as the polypeptide of SEQ ID NO:1.

In accordance with the present invention, nucleic acids having the appropriate sequence homology with a *Renilla* GFP synthetic nucleic acid molecule may be identified by using hybridization and washing conditions of appropriate stringency. For example, hybridizations may be performed, according to the method of Sambrook et al. (1989, supra), using a hybridization solution comprising: 5X SSC, 5X Denhardt's reagent, 1.0% SDS, 100 µg/ml denatured, fragmented salmon sperm DNA, 0.05% sodium pyrophosphate and up to 50% formamide. Hybridization is carried out at 37 - 42 °C for at least six hours. Following hybridization, filters are washed as follows: (1) 5 minutes at room temperature in 2X SSC and 1% SDS; (2) 15 minutes at room temperature in 2X SSC and 0.1% SDS; (3) 30 min - 1 h at 37 °C in 1X SSC and 1% SDS; (4) 2 h at 42-65 °C in 1X SSC and 1% SDS, changing the solution every 30 minutes.

One common formula for calculating the stringency conditions required to achieve hybridization between nucleic acid molecules of a specified sequence homology (Sambrook et al., 1989, supra):

$$T_m = 81.5\text{ }^{\circ}\text{C} + 16.6\text{Log} [\text{Na}^+] + 0.41(\% \text{ G+C}) - 0.63 (\% \text{ formamide}) - 600/\text{\#bp in duplex}$$

As an illustration of the above formula, using $[\text{N}^+] = [0.368]$ and 50% formamide, with GC content of 42% and an average probe size of 200 bases, the T_m is 57 °C. The T_m of a DNA duplex decreases by 1 - 1.5 °C with every 1% decrease in homology. Thus, targets with greater than about 75% sequence identity would be observed using a hybridization temperature of 42 °C.

The stringency of the hybridization and wash depend primarily on the salt concentration and temperature of the solutions. In general, to maximize the rate of annealing of the probe with its target, the hybridization is usually carried out at salt and temperature conditions that are 20 - 25 °C below the calculated T_m of the of the hybrid. Wash conditions should be as stringent as possible for the degree of identity of the probe for the target. In general, wash conditions are selected to be approximately 12 - 20 °C below the T_m of the hybrid. In regards to the nucleic acids of the current invention, a moderate stringency hybridization is defined as hybridization in 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 µg/ml denatured salmon sperm DNA at 42 °C, and wash in 2X SSC and 0.5% SDS at 55 °C for 15 minutes. A high stringency hybridization is defined as hybridization in 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 µg/ml denatured salmon sperm DNA at 42 °C, and wash in 1X SSC and 0.5% SDS at 65 °C for 15 minutes. A very high stringency hybridization is defined as hybridization in 6X SSC, SX Denhardt's solution, 0.5% SDS and 100 µg/ml denatured salmon sperm DNA at 42 °C, and wash in 0.1X SSC and 0.5% SDS at 65 °C for 15 minutes.

Nucleic acids of the present invention may be maintained as DNA in any convenient cloning vector. In a preferred embodiment, clones are maintained in plasmid cloning/expression vector, such as pBluescript (Stratagene, La Jolla, CA), which is propagated in a suitable *E. coli* host cell.

Renilla GFP nucleic acid molecules of the invention include DNA, RNA, and fragments thereof which may be single- or double-stranded. Thus, this invention provides oligonucleotides (sense or antisense strands of DNA or RNA) having sequences capable of hybridizing with at least one sequence of a nucleic acid

molecule encoding the protein of the present invention. Such oligonucleotides are useful as probes for detecting *Renilla* GFP genes or transcripts. In one preferred embodiment, oligonucleotides for use as probes or primers are based on rationally-selected amino acid sequences chosen from SEQ ID NO:1. In a more preferred
5 embodiment, the amino acid sequence used to base the oligonucleotide sequence on corresponds to amino acids 101 – 155 of the protein in SEQ ID NO:1. In another preferred embodiment, the sequence of amino acids from number 107 – 150 are used. In preferred embodiments, the amino acid sequence information is used to make degenerate oligonucleotide sequences as is commonly done by those skilled in
10 the art. In other preferred embodiments, the degenerate oligonucleotides are used to screen cDNA libraries from *Renilla* spp, especially *Renilla kollikeri*. In yet other preferred embodiments, *Halistaure* spp, *Phialidium* spp and other marine organisms are screened.

15 **IV. Uses of *Renilla* GFP nucleic acid molecules and *Renilla* GFP protein**

Renilla GFP can be used in any application where existing GFP is currently being used, as well as in new applications enabled by the novel properties of *Renilla* GFP. The GFP protein, or nucleic acids encoding the GFP protein, is
20 used as a marker of protein localization and/or gene expression. The GFP is used to particular advantage where the addition of exogenous substrates is impractical, as in applications involving living cells, high throughput screening, and large scale agricultural and environmental monitoring. This protein is successfully expressed in heterologous systems because the chromogenic hexapeptide of GFP cyclizes
25 spontaneously without the need of cofactors or enzymes.

Renilla GFP offers several advantages over *Aequorea* GFP that expand its range of applications. The much higher extinction coefficient of *Renilla* GFP enables *in vivo* expression methods where *Aequorea* GFP is too weak to detect. *Renilla* GFP's transparent absorbance window between 320 nm and 390 nm allows
30 this GFP to be used in double-labeling experiments that are impossible with *Aequorea* GFP. Fluorescent probes whose excitation and emission spectra are

suitable to be used as secondary probes with *Renilla* GFP include, but are not limited to DAPI. Noise subtraction (scatter and autofluorescence) can be accomplished more readily with *Renilla reniformis* GFP because the protein is transparent from 320 nm to 390 nm and from 525 nm to 700 nm. Such noise subtraction is extremely beneficial in facilitating the fluorometric monitoring of turbid cell suspensions (as in live cell promoter-driven HTS systems) or in remote sensing applications in agricultural or environmental monitoring, such as monitoring crop development or soil conditions. The high chemical stability of GFP in general, and *Renilla* GFP in particular, allows it to be used to advantage in assay kits and other applications that involve biochemical manipulations and/or long term storage.

The GFP can be detected in these methods in several ways. As with *Aequorea* GFP, *Renilla* GFP can most advantageously be detected by using its unique fluorescent properties. Any of the general techniques for detecting *Aequorea* GFP can also be used for *Renilla* GFP as long as the unique characteristics of the *Renilla* GFP excitation spectra are taken into consideration. *Renilla* GFP can also be detected using any methods applicable to general protein detection, for example the use of antibodies specific to *Renilla* GFP. Methods for both of these approaches are well known in the art.

Because GFP is part of a larger system of fluorescence, it has the potential to be combined with the other components of the system to advantage. Luciferin and the luciferin-binding protein from *Renilla* can be used with *Renilla* GFP to change the excitation profile of GFP. The need for a close association of the two proteins for energy transfer can be used to test for the physical proximity of proteins to which they are fused *in vivo*.

Renilla GFP is particular well suited for pairing with *Aequorea* GFP for fluorescence resonance energy transfer (FRET) measurements. Intracellular and extracellular reporting by FRET may be accomplished by coupling a blue-emitting Tyr66 variant of *Aequorea victoria* GFP (Y66H, Y66W, Y66F or the equivalent) to a green-emitting *Renilla reniformis* GFP. The interspecies (*Aequorea-Renilla*) FRET pairing is preferable to an intraspecies pairing (i.e. coupling an *Aequorea*

blue-emitting variant to an *Aequorea* green- or yellow-emitting variant). The main reason for choosing an interspecies FRET pair is that all variants of *Aequorea* GFP self-associate to form reversible dimers (homodimers and heterodimers) (Barbieri et al., in 11th International Symposium on Bioluminescence and Chemiluminescence Symposium Proceedings, 2000). Thus, when two color variants of *Aequorea* GFP are used together in FRET determinations (as with two-hybrid energy transfer assays, *in vivo*), it may be impossible to determine whether the targeted proteins are drawing together the two color variants of *Aequorea* GFP to form an energy transfer pair or whether the self-association of the two *Aequorea* GFP variants is producing a false positive signal that has nothing to do with protein-protein self-association of the targeted cellular proteins.

Additionally, *Renilla* GFP is better suited than *Aequorea* GFP for fluorimetric assays. There is no wavelength from 250 nm through 520 nm that does not excite *Aequorea* GFP to fluoresce. There is no transparent window in the *Aequorea* GFP excitation spectrum over this range. *Renilla* GFP, however, does have a transparent excitation window that extends from 320 nm to 390 nm. This extended region of transparency (found in *Renilla* GFP but not in *Aequorea* GFP) provides a mechanism for significant noise reduction in *Renilla* GFP-based fluorimetric assays (microtiter plates and other high throughput screening devices). This noise reduction (or signal-to-noise enhancement) can be accomplished by employing polychromatic excitation optics in the fluorimetric detector. Thus, by exciting at 365 nm, 488 nm and 546 nm, for example, scatter and autofluorescence stimulated by 365 nm excitation and/or by 546 nm excitation can be eliminated from the true GFP fluorescence excited at 488 nm. In some cell-based fluorimetric assays, polychromatic excitation of this sort could result in a 1000-fold improvement in signal-to-noise ratio, when comparing an *Aequorea*-based assay with a *Renilla*-based assay.

A. GFP Nucleic Acids

Green Fluorescent Protein nucleic acids may be used for a variety of purposes in accordance with the present invention. DNA, RNA, or fragments thereof may be used as probes to detect the presence of and/or expression GFP

genes. Methods in which GFP nucleic acids may be utilized as probes for such assays include, but are not limited to: (1) *in situ* hybridization; (2) Southern hybridization (3) Northern hybridization; and (4) assorted amplification reactions such as polymerase chain reactions (PCR)

5 The GFP nucleic acids of the invention may also be utilized as probes to identify related genes from other *Renilla* species or from other anthozoan coelenterates. As is well known in the art, hybridization stringencies may be adjusted to allow hybridization of nucleic acid probes with complementary sequences of varying degrees of homology.

10 As described above, GFP nucleic acids may be used to advantage to produce large quantities of substantially pure *Renilla* GFP, or selected portions or epitopes thereof. The protein is thereafter used for various commercial purposes, as described below. In a preferred embodiment of the invention, large amounts of the recombinant *Renilla* GFP can be made by *in vitro* or *in vivo* expression systems.

15 The GFP coding sequence can also be used as a reporter protein in transgenic cells or organisms. In a preferred embodiment of the invention, a *Renilla* GFP coding sequence is operably fused to the coding sequence of a protein of interest, an appropriate promoter region and termination region, and transformed into a cell. In this manner, the localization of a protein of interest can be
20 determined *in vivo*, using the fluorescent properties of the fused GFP protein. Fusions of this nature can localize proteins to specific structures of the cell, such as the cytoskeleton, plasma membrane, nucleus, mitochondria, secretory pathway, and can also be used to study, *in vivo*, dynamic changes in the distribution and/or turnover of proteins within the cell, or within an organism. Such fusion proteins
25 can also be used as an indicator of protein-protein interactions: the interaction a GFP fusion protein and a fusion protein comprised of a second fluorescent protein, i.e. anthozoan luciferase, may be detected by the resonance transfer of energy from one fluorescent molecule to the other.

 In another preferred embodiment, the GFP coding sequence is
30 operably-linked to a promoter region of interest and termination sequences, and used as a reporter gene to transform a cell. These transgenic cells can be used to

advantage to study the regulation of the promoter region of interest *in vivo* or to trace cell lineage. Such studies are expected to reveal many subtle aspects of promoter regulation due to the exquisite sensitivity of these GFP assays using *Renilla* GFP. In a particularly preferred embodiment, GFP nucleic acids are used to

5 construct specific cell lines for cell-based diagnostics. Screening for compounds that regulate specific promoters can be accomplished using custom-designed cell lines combined with robot-compatible methodology. This embodiment is particularly applicable for screening drugs, organic chemicals, pesticides, mutagens, carcinogens and teratogens. In another preferred embodiment, *Renilla reniformis*

10 GFP is used in agricultural or environmental applications as a reporter of plant stress, soil conditions, or crop development using remote fluorescence detecting technologies.

B. *Renilla* GFP

15 The GFP protein can be used as a label in many *in vitro* applications currently used. Purified GFP can be covalently linked to other proteins by methods well known in the art, and used as a marker protein. The purified GFP protein can be covalently linked to a protein of interest in order to determine localization. In particularly preferred embodiments, a linker of 4 to 20 amino acids is used to

20 separate GFP from the desired protein. This application may be used in living cells by micro-injecting the linked proteins. The GFP may also be linked chemically or genetically to antibodies and used thus for example in localization of antigens in fixed and sectioned cells, or in other immunological applications (e.g. dot blotting, western blotting) known to those skilled in the art. In the case of *Renilla* GFP-

25 antibody fusion proteins, GFP may be used in numerous immunological assays where a heavy chain polyclonal antibody fused to *Renilla* GFP at the C-terminus of the heavy chain may preclude the need for a secondary fluorometrically-tagged antibody.

The GFP may be linked to purified cellular proteins and used to

30 identify binding proteins and nucleic acids in assays *in vitro*, using methods well known in the art.

The GFP protein can also be linked to nucleic acids and used to advantage. Applications for nucleic acid-linked GFP include, but are not limited, to FISH (fluorescent *in situ* hybridization), and labeling probes in standard methods utilizing nucleic acid hybridization.

5 . The following examples are provided to describe the invention in greater detail. They are intended to illustrate, not to limit, the invention.

**Example 1: Cloning and Characterization of a cDNA from
Renilla reniformis: Artificial Gene Construction**

10

Construction of an artificial gene encoding the *R. reniformis* GFP was undertaken according to method of Stemmer et al; 1995 in "Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides" in GENE 164; 49-53 (1995).

15

Determination of a nucleotide sequence encoding GFP from *R. reniformis*

The amino acid sequence of GFP from *Renilla reniformis*, SEQ ID
20 NO:1, was back-translated to its corresponding nucleotide sequence as set forth in SEQ ID NO:2. A codon usage preference for bacteria/*E. coli* was specified. Additionally, several minor changes were made in nonessential sequence to allow the introduction of two restriction endonuclease cleavage sites, and to encode a Histidine tag at the carboxy terminus to allow for easy of purification of the
25 expressed protein. A cleavage site for *NdeI* (CATATG) was added immediately upstream of the AUG codon for the N-terminal methionine, and a *XhoI* cleavage site (CTCGAG) was engineered at the carboxyl terminus. Several additional amino acids were added to the C-terminus including a polyhistidine tag. GFP is particularly amenable to fusion with other proteins or short polypeptides and these
30 in no way interfere with the desirable properties or expression of the protein. The complete amino acid sequence encoded by the open reading frame of the modified,

back-translated nucleotide of SEQ ID NO:2 is set forth as the amino acid sequence SEQ ID NO:3.

Gene Assembly:

5 Strategic Selection of Synthetic Oligonucleotides:

A series of oligonucleotides corresponding to the each of the complementary strands of the back-translated nucleotide sequence were prepared according to the strategy outlined by Stemmer et al (1995, supra). According to the strategy, a series of consecutive oligonucleotides, which in their entirety comprise
10 the full length of the back-translated nucleotide sequence, were generated. The nineteen oligonucleotides, SEQ ID NOs:4 through 22, hereinafter the upper primers, were each 40-mer oligonucleotides corresponding to the first (upper) strand of the back-translated sequence provided in SEQ ID NO:2. The nineteen oligonucleotides SEQ ID NOs:23 through 41, hereinafter the lower primers, were
15 each 40-mer oligonucleotides corresponding to the second (lower) strand of the back-translated sequence (i.e. the complement of SEQ ID NO:2). Oligonucleotides 4 – 41 were purchased from Integrated DNA Technologies (IDT, Coralville, IA).

DNA polymerase helps to create the full-length gene

20 Each oligonucleotide is constructed to have a 20-nucleotide "overlap" of complementarity with its neighbor oligonucleotides on the opposing strand. Under proper conditions of stringency, the set of consecutive oligonucleotides will hybridize with its neighbors. The set of upper and lower primers are mixed in equal concentration under proper conditions and *Taq* DNA polymerase is added. Under
25 PCR conditions, repeated cycles of DNA polymerase action on the hybridized, aligned and overlapping oligonucleotides eventually yield the full-length properly assembled gene.

Gene Amplification:

30 An aliquot of the reaction mixture from the Gene Assembly step containing the full-length product above is then amplified via PCR with *Taq* DNA

polymerase, in the presence of dNTPs, and, as primers, the oligonucleotides corresponding to the 5' ends of both the upper and lower strands of the back-translated SEQ ID No:1.

5 The product of the gene assembly step is purified and separated by electrophoresis on 1% agarose gel. The purified product is digested with *NdeI* and *XhoI* restriction endonucleases; the plasmid pET24A (Novagene, Madison, WI) is likewise digested with the same enzymes. The fragment and the plasmid are ligated, and transformed into *E. coli*.

10

Characterization of the GFP clone:

Transformants containing the plasmid are grown and plasmid DNA is obtained. The clone is sequenced to verify the proper full-length clone has been selected. The GFP clone is inserted in frame with the His tag of the expression
15 plasmid. The plasmid is then used in expression experiments, to generate quantities of the cloned GFP protein. The protein is readily purified and the His tag facilitates purification via immobilized metal affinity chromatography, which provides great advantage in rapid purification.

20 The purified protein can be used to generate batches of standardized cloned GFP with reproducible spectral properties, and is used for calibration of instruments or assays.

Example 2: Cloning of a cDNA encoding GFP from *Renilla*

25 *reniformis*

The cloning of an intact, full-length cDNA encoding GFP from *Renilla reniformis* was undertaken according to the method of Matz et al. (Nature Biotechnology 17: 969-973, 1999).

30

Isolation of mRNA from *R. reniformis*: The total RNA from the sea pansy, *R. reniformis*, was isolated using a Stratagene RNA isolation kit. Subsequently, mRNA was isolated from the total RNA with the magnetic PolyA Tract mRNA Isolation System III (Promega).

5

Back-Translation Protein Sequence and Design of Primers: The amino acid sequence of the *Renilla* GFP, as set forth in SEQ ID NO:1, was used to generate a back-translated nucleotide sequence as set forth in SEQ ID NO:2. The nucleotide sequence was selected for codon usage bias of *E. coli*. The sequence in this back-translated sequence was used to design two oligonucleotide primers, GSP1 and GSP2, respectively SEQ ID Nos:44 and 45. The first primer GSP1 was used in conjunction with SMART PCR (below) to obtain a nucleotide fragment corresponding to the C-terminus. Nested PCR is performed to obtain sequence towards the N-terminus.

15

SMART PCR cDNA Synthesis and Amplification: A SMART PCR cDNA synthesis Kit (Clontech) was used for the first strand cDNA synthesis from polyA mRNA. The manufacturer's protocol (SMART PCR cDNA Synthesis Kit User Manual PT3041-1, Published 27, April 1999 by Clontech which is herein incorporated by reference in its entirety), except that the TN3 primer (5'-CGCAGTCGACCG(T)13), SEQ ID NO:42, was used instead of the kit's CDS primer.

The cDNA population was amplified by PCR using the primers TS (5'-AAGCAGTGGTATCAACGCAGAGT), SEQ ID NO:43 and TN3, SEQ ID NO:42 (and above), each at 0.1 μ m. The cDNA was diluted 20-fold with water and 1 μ l of this was used in the PCR reaction as described in the kit instructions.

Modified 3' RACE of the GFP: A gene-specific primer, designated GSP1 was designed. The primer was purchased from IDT (IA) and had the sequence set forth in SEQ ID NO:44. The first of two PCR steps used the GSP1

30

and TN3 primers. An aliquot of 1 μ l of a 20-fold diluted cDNA mixture of the amplified cDNA was added to a reaction mixture containing Advantage KlenTaq Polymerase mix (Clontech), the manufacturer's 1X reaction buffer, 200 μ M dNTPs (Gibco BRL), 0.3 μ M GSP1 and 0.1 μ M TN3 primer in a total volume of 20 μ l.

- 5 Cycling was performed in a Perkin Elmer Gene Amp PCR System 2400. PCR conditions included: 1 cycle of: 95 C for 10 s, 55 C for 1 min, 72 C for 40 s and 24 cycles of: 95 C for 10 s, 62 C for 30 s and 72 C for 40 s.

- 10 The reaction products were then diluted 20-fold and 1 μ l of the diluted mixture are added to a second PCR which contained Advantage KlenTaq Polymerase mix (Clontech), the manufacturer's 1X reaction mix, 200 μ M dNTPs (Gibco BRL), 0.3 μ M primer GSP2 (SEQ ID NO:45), and 0.1 μ M TN3 primer in a total volume of 20 μ l. The PCR conditions were as follows: 1 cycle of 95 C for 10 s, 55 C for 1 min, 72 C for 40 s; then 13 cycles of 95 C for 10 s, 62 C for 30 s and 72 C for 40 s.

15

- 20 The 5' end of the cDNA is obtained by following the method of Modified 5' RACE PCR. The 3' fragment is isolated from the PCR and sequenced. A 3' gene-specific primer is designed to function in PCR with a 5' primer. In other words, the cloned 3' end of the cDNA is combined with a cloned 5' end of the cDNA obtained, both fragments obtained via Modified RACE PCR. The fragments are aligned, ligated together, and cloned as a full-length cDNA.

- 25 Characterization of the full-length cDNA: The full-length cDNA is sequenced to verify the integrity of the clone. The deduced amino acid sequence of the open reading frame is also compared with the amino acid sequences in SEQ ID NO:1. After sequencing, the full-length PCR fragment is inserted into the expression vector pET24A (Novagene). The protein is then expressed in large quantity in an *E. coli* expression system.

30

**Example 3: Purification and Characterization of GFP from
*Renilla kollikeri***

Purification:

5 Starting with approximately 2 kg of sea pansy (*Renilla kollikeri*), the method of Gonzalez & Ward for large-scale purification of GFP from *E. coli* was followed (Daniel G Gonzalez and William W Ward; "Large scale Purification of Recombinant Green Fluorescent Protein from *Escherichia coli*" pp212-223 Methods in Enzymology; Volume 305; Bioluminescence and Chemiluminescence; Part C; 10 edited by Miriam M. Ziegler and Thomas O Baldwin; Academic Press; 2000).

Characterization:

 The purification yielded about 1 mg of purified GFP. The absorbance spectrum of the GFP from *R. kollikeri* was identical with that of *R.*
15 *reniformis*, including the near-transparent window of absorption between 320 – 390 nm (Fig.1). The behavior of the protein throughout the purification scheme was substantially similar to that of the *R. reniformis* GFP. This is evidence of the similarity of physical, chemical and biochemical properties between the two GFPs.

20 Determination of Amino Acid Sequence:

 Samples of the purified GFP are chemically and/or enzymatically digested to generate fragments. These fragments are subjected to HPLC and mass spectroscopy, and the characterized and isolated fragments are then subjected to sequencing via automated Edman degradation. The final sequence of the GFP is
25 assembled by alignment of overlapping sequences of the fragments. Comparisons are made to the sequence of the completed *R. reniformis* to speed analysis of the completed fragment data. The complete sequence is substantially identical to that of *R. reniformis*. Certain conservative amino acid substitution are acceptable in nonessential areas of the protein (i.e. those not critical for the function of the
30 chromophore, and those not critical to maintaining the tertiary structure of the folded protein).

Cloning *R. kollikeri* cDNA:

In addition to the protein sequence, clones are obtained from *R. kollikeri*. The cDNA from *R. reniformis* is used as a probe to identify genomic and/or cDNA clones. Isolated *R. kollikeri* polyA mRNA is used as a source of full-length mRNA corresponding to the GFP. Standard techniques are used to prepare a cDNA library containing the desired sequence. The cDNA is placed into a vector appropriate for expression in the desired organism. Alternatively, a series of oligonucleotides corresponding to each strand of the full length of a back-translation of the *R. kollikeri* GFP amino acid sequence is prepared. The overlapping oligonucleotides are annealed and ligated to create a synthetic GFP gene. Strategic placement of proper cloning sites (e.g. restriction endonuclease cleavage sites) allows the synthetic GFP gene to be placed into a proper cloning vector. Sequencing of the cloned nucleic acid is performed to verify that the clone is correct and of full length. The selected vector is appropriate for expression in a desired system, for example, pET24A (Novagene) for expression in *E. coli*. The cDNA is optimized for expression in the desired organism by adapting the sequence to the codon usage preferences of the desired organism. Large-scale preparation or commercial production of the GFP is enabled by the availability of the cloned GFP and an appropriate expression system.

The present invention is not limited to the embodiments described and exemplified above, but is capable of variation and modification without departure from the scope of the appended claims.

What is claimed:

1. An isolated polypeptide having an amino acid sequence that confers upon the polypeptide physical and biochemical properties of a green fluorescent protein (GFP) from *Renilla reniformis* or *Renilla kollikeri*.
2. The isolated polypeptide of claim 1, further comprising a GFP chromophore.
3. The isolated polypeptide of claim 1, further comprising excitation spectrum peaks at 470 nm and 498 nm.
4. The isolated polypeptide of claim 1, further comprising a region of low absorbance of light energy in the range from 320 nm to 390 nm.
5. A variant of the isolated polypeptide of claim 1, having an excitation or emission spectra that is different from the excitation or emission spectra of a native GFP from *Renilla reniformis* or *Renilla kollikeri*.
6. The isolated polypeptide sequence of claim 1 comprising an amino acid sequence substantially the same as the *Renilla reniformis* sequence set forth in SEQ ID NO:1.
7. An isolated GFP comprising an amino acid sequence substantially the same as a sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.
8. The isolated GFP of claim 7 which includes a GFP chromophore.
9. The isolated GFP of claim 7 further comprising excitation and emission spectra of a *Renilla* GFP.

10. The isolated GFP of claim 9 which has an extinction coefficient equal to or greater than $70,000 \text{ L mol}^{-1} \text{ cm}^{-1}$ and a quantum yield of at least 0.5.

5 11. A variant of the isolated GFP of claim 7, having an excitation or emission spectra that is different from the excitation or emission spectra of a native GFP from *Renilla reniformis* or *Renilla kollikeri*.

10 12. An isolated or synthesized nucleic acid molecule which encodes the polypeptide of claim 1.

13. The nucleic acid of claim 12 wherein the sequence is substantially the same as the sequence set forth in SEQ ID 2.

15 14. The nucleic acid molecule of claim 12 further comprising sequence modifications selected from the group consisting of: adding or removing one or more restriction endonuclease cleavage sites, changing codon usage to optimize the sequence for expression in a selected organism, adding or removing one or more amino acids, and site-directed mutagenesis changes of one or more
20 amino acids.

15. The nucleic acid molecule of claim 12, further comprising a sequence optimized for expression in an organism selected from the group consisting of bacteria, yeast, insects, plants and mammals.

25

16. An isolated nucleic acid molecule which encodes the polypeptide of claim 7.

18. Isolated antibodies of which specifically recognize and bind
30 antigenic epitopes of *Renilla* GFP.

19. The isolate antibodies of claim 18 which specifically recognize and bind antigenic epitopes present in the polypeptide having the amino acid sequence set forth in SEQ ID NO:1.

5 20. An antibody-GFP complex comprising noncovalent interaction between an antibody specific for *Renilla* GFP and the GFP recognized by said antibody.

21. A fusion protein comprising an antibody, or functional portion
10 thereof, and a GFP.

22. A GFP standard comprising a composition of *Renilla* GFP with known physical, biochemical and biophysical properties.

15 23. The GFP standard of claim 22 wherein one or more of the extinction coefficient, quantum yield or other useful biophysical or spectral properties are predetermined.

24. The GFP standard of claim 23 used as a standard for calibration
20 of instruments.

25 25. The GFP standard of claim 24 wherein the instrument is selected from the group consisting of: high-throughput screening monitors, fluorometers, fluorescence microscopes, fluorescence detectors, fluorescence activated cell sorters, flow cells, flow monitors, fluorescence spectrometers, fluorescence polarization instruments, x-ray fluorescence instruments, fluorescence imaging instruments, ratio fluorescence instruments, spectrofluorometers, fluorescence scanners, fluorescence-based microplate readers, fluorescence-based nucleic acid sequencing systems, laser- and laser diode-based fluorescence instruments, and
30 charge-coupled device (CCD)-based fluorescence instruments.

26. A method of calibrating fluorescence-based biological assays with the GFP standard of claim 21, comprising one or more of the steps of:

- 5 a) adjusting a fluorescence reading instrument with a known amount of the GFP standard;
- b) creating standard curves with the GFP standard, according to the conditions of the biological assay;
- c) maintaining the instrument in proper calibration by checking periodically with the GFP standard;
- 10 d) comparing each assay or batch of assays performed with assay standard curve;
- e) referring to the assay standard curve for accurate quantitation of the assay; and
- 15 f) including internal controls with each assay or batch of assays by adding a known amount of the GFP standard to an assay sample.

27. A kit for the calibration of fluorescence-based instruments and assays comprising:

- 20 a) the standard GFP of claim 21, and optionally, one or more of;
- b) a series of concentrations of the GFP standard;
- c) a certificate of quality control indicating batch and control numbers, concentrations of the standards and
- 25 biophysical data about the standards; and
- d) instructions for use of the kit to calibrate fluorescence-based instruments and biological assays.

28. An oligonucleotide for use as a primer or in screening or cloning new GFP-related molecules, comprising a nucleotide sequence derived from a nucleic acid molecule encoding the amino acid sequence set forth as SEQ ID NO:1.

5 29. The oligonucleotide of claim 28 wherein the nucleotide sequence encodes amino acids 101 – 155 of SEQ ID NO:1.

30. The oligonucleotide of claim 28 wherein the nucleotide sequence encodes the amino acids 107 – 150 of SEQ ID NO:1.

10

31. An oligonucleotide for use as a primer or in screening for new GFP-related molecules comprising a nucleotide sequence derived from a portion of the nucleotide sequence set forth as SEQ ID NO:2.

15 32. A method for reducing background noise and optimizing signal in fluorescence-based biological assays comprising one or more of the steps of:

a) using a GFP with a low absorbance window at one or more points in the spectrum, and high absorption and emission at other points in the spectrum;

20 b) using polychromatic filters to ensure that light of the proper wave lengths can be selected for the assay;

c) determining one or more optimum wavelengths for excitation and emission measurement based on the maximum light emitted from the sample versus the lowest amount of quenching, interference and nonspecific absorption from assay components; and

25

d) using a standard GFP for comparison and to determine loss of signal, quenching and energy transfer efficiency.




FIG. 1

SEQUENCE LISTING

<110> Rutgers, The State University of New Jersey
Ward, William W.
Thomson, Catherine M.

<120> Renilla reniformis Green Fluorescent
Protein

<130> RUTC-99-0021

<150> 60/162,584
<151> 1999-10-29

<150> 60/213,093
<151> 2000-06-21

<150> 60/223,805
<151> 2000-08-08

<160> 45

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 237
<212> PRT
<213> Renilla reniformis

<220>
<221> VARIANT
<222> 124
<223> Xaa = Tyr or conservative substitution

<221> VARIANT
<222> 125
<223> Xaa = Lys or Arg

<221> VARIANT
<222> 126
<223> Xaa = Gly or conservative substitution

<221> VARIANT
<222> 127
<223> Xaa = Asn or Ser

<221> VARIANT
<222> 128
<223> Xaa = Lys or absent

<221> VARIANT
<222> 129
<223> Xaa = Asp, Gly, or Asn

<221> VARIANT
<222> 130
<223> Xaa = Leu or Pro

<221> VARIANT
<222> 131
<223> Xaa = Arg or Pro

<221> VARIANT

<222> 132
 <223> Xaa = Glu, Arg, Leu, Ser or Asp

 <221> VARIANT
 <222> 162
 <223> Xaa = Cys, Trp, or Thr

 <221> VARIANT
 <222> 217
 <223> Xaa = Thr or Glu

 <221> VARIANT
 <222> 218
 <223> Xaa = Thr or Gly

 <221> VARIANT
 <222> 235
 <223> Xaa = Glu or conservative substitution or
 alternatively absent

 <221> VARIANT
 <222> 236
 <223> Xaa = Met or conservative substitution or
 alternatively absent

 <221> VARIANT
 <222> 237
 <223> Xaa = Val or conservative substitution or
 alternatively absent

 <400> 1
 Met Asp Leu Ala Lys Leu Gly Leu Lys Glu Val Met Pro Thr Lys Ile
 1 5 10 15
 Asn Leu Glu Gly Leu Val Gly Asp His Ala Phe Ser Met Glu Gly Val
 20 25 30
 Gly Glu Gly Asn Ile Leu Glu Gly Thr Gln Glu Val Lys Ile Ser Val
 35 40 45
 Thr Lys Gly Ala Pro Leu Pro Phe Ala Phe Asp Ile Val Ser Val Ala
 50 55 60
 Phe Ser Tyr Gly Asp Arg Ala Tyr Thr Gly Tyr Pro Glu Glu Ile Ser
 65 70 75 80
 Asp Tyr Phe Leu Gln Ser Phe Pro Glu Gly Phe Thr Tyr Glu Arg Asn
 85 90 95
 Ile Arg Tyr Gln Asp Gly Gly Thr Ala Ile Val Lys Ser Asp Ile Ser
 100 105 110
 Leu Glu Asp Gly Lys Phe Ile Val Asn Val Glu Xaa Xaa Xaa Xaa
 115 120 125
 Xaa Xaa Xaa Xaa Met Gly Pro Val Met Gln Gln Asp Ile Val Gly Met
 130 135 140
 Gln Pro Ser Tyr Glu Ser Met Tyr Thr Asn Val Thr Ser Val Ile Gly
 145 150 155 160
 Glu Xaa Ile Ile Ala Phe Lys Leu Gln Thr Gly Ile His Phe Thr Tyr
 165 170 175
 His Met Arg Thr Val Tyr Lys Ser Lys Lys Pro Val Glu Thr Met Pro
 180 185 190
 Leu Tyr His Phe Ile Gln His Arg Leu Val Lys Thr Asn Val Asp Thr
 195 200 205
 Ala Ser Gly Tyr Val Val Gln His Xaa Xaa Ala Ile Ala Ala His Ser
 210 215 220
 Thr Ile Lys Lys Ile Glu Gly Ser Leu Pro Xaa Xaa Xaa
 225 230 235

<210> 2

<211> 780
 <212> DNA
 <213> Renilla reniformis

<220>
 <221> CDS
 <222> (23)...(766)

<400> 2

```

actttaagaa ggagatatac at atg gat ctg gcg aaa ctg ggt ctg aaa gaa 52
                        Met Asp Leu Ala Lys Leu Gly Leu Lys Glu
                        1                      5                      10

gtg atg ccg act aaa att aac ctg gaa ggt ctg gtg ggt gat cat gcg 100
Val Met Pro Thr Lys Ile Asn Leu Glu Gly Leu Val Gly Asp His Ala
                        15                      20                      25

ttt agc atg gaa ggt gtg ggt gaa ggt aac att ctg gaa ggt acc cag 148
Phe Ser Met Glu Gly Val Gly Glu Gly Asn Ile Leu Glu Gly Thr Gln
                        30                      35                      40

gaa gtg aaa att agc gtg acc aaa ggt gcg ccg ctg ccg ttt gcg ttt 196
Glu Val Lys Ile Ser Val Thr Lys Gly Ala Pro Leu Pro Phe Ala Phe
                        45                      50                      55

gat att gtg agc gtg gcg ttt agc tat ggt gat cgt gcg tat acc ggt 244
Asp Ile Val Ser Val Ala Phe Ser Tyr Gly Asp Arg Ala Tyr Thr Gly
                        60                      65                      70

tat ccg gaa gaa att agc gat tat ttt ctg cag aaa ttt ccg gaa ggt 292
Tyr Pro Glu Glu Ile Ser Asp Tyr Phe Leu Gln Lys Phe Pro Glu Gly
                        75                      80                      85

ttt acc tat gaa cgt ggt aac att cgt tat cag gat ggt ggt acc gcg 340
Phe Thr Tyr Glu Arg Gly Asn Ile Arg Tyr Gln Asp Gly Gly Thr Ala
                        95                      100                      105

att gtg aaa agc gat att agc ctg gaa gat ggt aaa ttt att gtg aac 388
Ile Val Lys Ser Asp Ile Ser Leu Glu Asp Gly Lys Phe Ile Val Asn
                        110                      115                      120

gtg gaa tat aaa ggt agc aaa gac ctg cgt gaa atg ggt ccg gtg atg 436
Val Glu Tyr Lys Gly Ser Lys Asp Leu Arg Glu Met Gly Pro Val Met
                        125                      130                      135

cag cag gat att gtg ggt atg cag ccg agc tat gaa agc atg tat acc 484
Gln Gln Asp Ile Val Gly Met Gln Pro Ser Tyr Glu Ser Met Tyr Thr
                        140                      145                      150

aac gtg acc agc gtg att ggt gaa ggt att att gcg ttt aaa ctg cag 532
Asn Val Thr Ser Val Ile Gly Glu Gly Ile Ile Ala Phe Lys Leu Gln
                        155                      160                      165

acc ggt att cat ttt acc tat cac atg cgt acc gtg tat aaa agc aaa 580
Thr Gly Ile His Phe Thr Tyr His Met Arg Thr Val Tyr Lys Ser Lys
                        175                      180                      185

aaa ccg gtg gaa acc atg ccg ctg tat cat ttt att cag cat cgt ctg 628
Lys Pro Val Glu Thr Met Pro Leu Tyr His Phe Ile Gln His Arg Leu
                        190                      195                      200

gtg aaa acc aac gtg gat acc gcg agc ggt tat gtg gtg cag cat gaa 676
Val Lys Thr Asn Val Asp Thr Ala Ser Gly Tyr Val Val Gln His Glu
                        205                      210                      215

```

acc gcg att gcg gcg cat agc acc att aaa aaa att gaa ggt gcg gcg 724
 Thr Ala Ile Ala Ala His Ser Thr Ile Lys Lys Ile Glu Gly Ala Ala
 220 225 230

cgt gaa tgg cgt tct ctc gag cac cac cac cac cac tga 766
 Arg Glu Trp Arg Ser Leu Glu His His His His His His *
 235 240 245

gatccggctg ctaa 780

<210> 3
 <211> 247
 <212> PRT
 <213> Renilla reniformis

<400> 3
 Met Asp Leu Ala Lys Leu Gly Leu Lys Glu Val Met Pro Thr Lys Ile
 1 5 10 15
 Asn Leu Glu Gly Leu Val Gly Asp His Ala Phe Ser Met Glu Gly Val
 20 25 30
 Gly Glu Gly Asn Ile Leu Glu Gly Thr Gln Glu Val Lys Ile Ser Val
 35 40 45
 Thr Lys Gly Ala Pro Leu Pro Phe Ala Phe Asp Ile Val Ser Val Ala
 50 55 60
 Phe Ser Tyr Gly Asp Arg Ala Tyr Thr Gly Tyr Pro Glu Glu Ile Ser
 65 70 75 80
 Asp Tyr Phe Leu Gln Lys Phe Pro Glu Gly Phe Thr Tyr Glu Arg Gly
 85 90 95
 Asn Ile Arg Tyr Gln Asp Gly Gly Thr Ala Ile Val Lys Ser Asp Ile
 100 105 110
 Ser Leu Glu Asp Gly Lys Phe Ile Val Asn Val Glu Tyr Lys Gly Ser
 115 120 125
 Lys Asp Leu Arg Glu Met Gly Pro Val Met Gln Gln Asp Ile Val Gly
 130 135 140
 Met Gln Pro Ser Tyr Glu Ser Met Tyr Thr Asn Val Thr Ser Val Ile
 145 150 155 160
 Gly Glu Gly Ile Ile Ala Phe Lys Leu Gln Thr Gly Ile His Phe Thr
 165 170 175
 Tyr His Met Arg Thr Val Tyr Lys Ser Lys Lys Pro Val Glu Thr Met
 180 185 190
 Pro Leu Tyr His Phe Ile Gln His Arg Leu Val Lys Thr Asn Val Asp
 195 200 205
 Thr Ala Ser Gly Tyr Val Val Gln His Glu Thr Ala Ile Ala Ala His
 210 215 220
 Ser Thr Ile Lys Lys Ile Glu Gly Ala Ala Arg Glu Trp Arg Ser Leu
 225 230 235 240
 Glu His His His His His His
 245

<210> 4
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic Sequence

<400> 4
 actttaagaa ggagatatat atatggatct ggcgaaactg 40

<210> 5
 <211> 40

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 5
ggctctgaaag aagtgatgcc gactaaaatt aacctggaag 40

<210> 6
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 6
gtctggtggg tgatcatgcg tttagcatgg aagggtgagg 40

<210> 7
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 7
tgaaggtaac attctggaag gtaccagga agtgaaaatt 40

<210> 8
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 8
agcgtgacca aagggtgcgcc gctgccgttt gcgtttgata 40

<210> 9
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 9
ttgtgagcgt ggcgttttagc tatggtgatc gtgcgtatac 40

<210> 10
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 10
cggttatccg gaagaaatta gcgattatct tctgcagaaa 40

<210> 11
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 11
tttccggaag gttttaccta tgaacgtggt aacattcggt 40

<210> 12
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 12
atcaggatgg tggtagcgcg attgtgaaaa gcgatattag 40

<210> 13
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 13
cctggaagat ggtaaattta ttgtgaacgt ggaatataaa 40

<210> 14
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 14
ggtagcaaag acctgcgtga aatgggtccg gtgatgcagc 40

<210> 15
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 15
aggatattgt gggtagcag ccgagctatg aaagcatgta 40

<210> 16
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 16

taccaacgtg accagcgtga ttggtgaagg tattattgcg 40

<210> 17
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 17
tttaaactgc agaccggtat tcattttacc tatcacatgc 40

<210> 18
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 18
gtaccgtgta taaaagcaaa aaaccggtgg aaaccatgcc 40

<210> 19
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 19
gctgtatcat ttatttcagc atcgtctggt gaaaaccaac 40

<210> 20
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 20
gtggataccg cgagcgggta tgtggtgcag catgaaaccg 40

<210> 21
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 21
cgattgcggc gcatagcacc attaaaaaaaa ttgaaggtgc 40

<210> 22
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 22
ggcgcgtgaa tggcgttttc tcgagcacca ccaccaccac 40

<210> 23
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 23
gtggtggtgg tggcgctcga gagaacgcca ttcacgcgcc 40

<210> 24
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 24
gcaccttcaa tttttttaat ggtgctatgc gccgcaatcg 40

<210> 25
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 25
cggtttcatg ctgcaccaca taaccgctcg cggtatccac 40

<210> 26
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 26
gttgggtttc accagacgat gctgaataaa atgatacagc 40

<210> 27
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 27
ggcatgggtt ccaccggttt tttgctttta tacacggtac 40

<210> 28
<211> 40
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 28

gcatgtgata ggtaaaatga ataccggtct gcagtttaaa

40

<210> 29

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 29

cgcaataata ccttcaccaa tcacgctggt cacgttggtta

40

<210> 30

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 30

tacatgcttt catagctcgg ctgcataccc acaatatacct

40

<210> 31

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 31

gctgcatcac cggacccatt tcacgcaggt ctttgctacc

40

<210> 32

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 32

tttatattcc acgttcacaa taaatttacc atcttccagg

40

<210> 33

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 33

ctaataatgc ttttcacaat cgcggtacca ccatcctgat

40

<210> 34

<211> 40

<212> DNA

<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 34
aacgaatggt accacgttca taggtaaaac cttccggaaa 40

<210> 35
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 35
tttctgcaga aaataatcgc taatttcttc cggataaccg 40

<210> 36
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 36
gtatacgcac gatcaccata gctaaacgcc acgctcacia 40

<210> 37
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 37
tatcaaacgc aaacggcagc ggcgcacctt tggtcacgct 40

<210> 38
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 38
aatcttcact tcctgggtac cttccagaat gttaccttca 40

<210> 39
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 39
cccacacctt ccattgctaaa cgcattgatca cccaccagac 40

<210> 40
<211> 40
<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 40

cttccagggt aatttttagtc ggcatacactt ctttcagacc

40

<210> 41

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 41

cagtttcgcc agatccatat gtatatctcc ttcttaaagt

40

<210> 42

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 42

cgcagtcgac cgtttttttt ttttt

25

<210> 43

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 43

aagcagtggg atcaacgcag agt

23

<210> 44

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 44

gatatacata tgggtccggg gatgcag

27

<210> 45

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 45

gatatacata tgtctgatat ttcatta

27

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/29976

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07K 1/00, C12Q 1/00

US CL : 530/350, 435/4

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350, 855, 324; 435/4, 8, 6, 69.1, 69.7; 536/23.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WARD, et al. An Energy Transfer Protein in Coelenterate Bioluminescence. J. Biol. Chem. February 1979, Vol 254, pages 781-788; pages 784-786, Table II, III, Fig. 4.	1-4
X	WO 99/49019 A2 (PROLUME LTD.) 30 September 1999, pages 13-14, 17-18, 25, 75-77, 80, 89, 146-148, Fig 3-5.	1-4
Y	US 5,777,079 A (TSIEN et al) 07 July 1998, columns 2-7, Table I, II.	5, 11
A	US 4,231,750 A (DOWBEN et al) 04 November 1980, columns 1, 5-13, and examples.	26

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"Z" document member of the same patent family
"P" documents published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search:

22 January 2001 (22.01.2001)

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. (703)305-3230

Date of mailing of the international search report

23 FEB 2001

Authorized officer

Chih-Min Kam

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/29976

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-11, 26

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/29976

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I. Claims 1-11 and 26, drawn to an isolated polypeptide and a method using the polypeptide.

Group II. Claims 12-16, drawn to an isolated nucleic acid.

Group III. Claims 18-19, drawn to an isolated antibody.

Group IV. Claim 20, drawn to an antibody-GFP complex.

Group V. Claim 21, drawn to a fusion protein of an antibody and a GFP.

Group VI. Claims 22-25, drawn to a GFP standard.

Group VII. Claim 27, drawn to a kit for calibration of fluorescence-based instruments and assays.

Group VIII. Claims 28-31, drawn to an oligonucleotide used as a primer.

Group IX. Claim 32, drawn to a method of reducing background noise and optimizing signal in fluorescence-based biological assays.

The inventions listed as Groups I-IX do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: In this instance, the green fluorescent protein (GFP) is known in the art, see Ward and Cormier, 1979, J. Biol. Chem. 254, 781-788. Thus, the special technical feature is known and the claimed subject matter does not define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.

Continuation of B. FIELDS SEARCHED Item 3: STN search on caplus, medline, embase, biosis and scisearch; EAST search on USPAT, DDERWENT, EPO, and JPO. Search terms used: green fluorescent protein, GFP, renilla, renilla reniformis, renilla killokeri, fluorescence with assays with standard curve.